Middle East and North Africa (MENA) Life Sciences Industry Outlook, Forecast to 2020

Middle East and North Africa (MENA) Life Sciences Industry Outlook, Forecast to 2020

Increased Local Manufacturing and Government Spending on Lifestyle Diseases to be Key Driving Factors in 2020

RELEASE DATE
23-Aug-2019
REGION
South Asia, Middle East & North Africa
Research Code: PA76-01-00-00-00
SKU: HC03208-SA-MO_23534

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03208-SA-MO_23534

$4,950.00

$3,712.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

In this research deliverable, Frost & Sullivan’s analyst team provides bold perspectives and predictions for the Middle East and North Africa (MENA) region’s life sciences industry in 2020. The markets covered include pharmaceuticals, biotechnology, and in-vitro diagnostics. The analysis captures the impact of trends that are expected to transpire over 2019 and 2020 as organizations prepare for the future. This study provides guidance on where to find the greatest opportunities for expansion and which key companies to look out for.

Frost & Sullivan projects the MENA Life Sciences market to cross US$ 40 billion by 2020. A shift in the focus of healthcare towards lifestyle-driven chronic health conditions and an increasingly affluent population’s preference for research-based branded drugs and preventive screening diagnostic tests are expected to drive the MENA life sciences market during the forecast period (2019 to 2020). Ongoing economic diversification and localization efforts by governments will make the domestic production of branded generic drugs more important than ever for both local consumption and export services. In addition, the regulatory environment will see a major transformation in each country. Given the on-going localization trends, it will be critical for global pharma MNCs to strategically collaborate with local agents or CMOs for their expertise on domestic contacts, customs regulations, and faster time to market in the MENA region. Areas exhibiting high growth opportunities will be the main focus of governments and industries alike. Business models specific to MENA will be pursued in contrast to those in larger markets of developed nations. Mergers and acquisitions are expected as stakeholders collaborate to achieve common outcomes. The outlook foresees increased collaboration and M&A activities between the life sciences and other healthcare sectors, in which preventative digital technology innovations will support the prevention of the onset of chronic and genetic diseases. Health spending is expected to rise in the region with governments aiming to meet sustainable development goals.


Research Highlights

  • Market overview and projections for the MENA life sciences market in 2020
  • Revenue forecast by key MENA life sciences markets
  • Key predictions for the life sciences market in 2020 by segment
  • Key trends and growth opportunities affecting the MENA life sciences market
  • Strategic recommendations and future outlook of the life sciences market

Key Issues Addressed

  • What are the key predictions for the 2020 MENA life sciences market?
  • What is the market projection for MENA pharmaceutical/biotechnology and IVD markets for 2020?
  • Which are the most preferred countries in MENA for the localization of future drug manufacturing activities?
  • What are key growth opportunities in the MENA pharma and IVD industry for 2020?
  • Who are the companies to watch in the MENA region for the life sciences market?
  • What policies and regulatory developments will affect your company’s MENA operations in 2020?
  • What are the monetization opportunities for the life science industry as major GCC countries aim to diversify towards a service-based economy?

Author: Kamaljit Behera

Table of Contents

Key 2020 MENA Life Sciences Predictions

Research Scope

MENA Life Sciences Industry Revenue, 2018–2020

2020 MENA Regional Life Sciences Perspective

Prediction 1—Localization of Pharma Manufacturing

Prediction 2—NGS Testing Awareness and Adoption Increases

Prediction 3—Rise in Middle East Budget for Diabetes and Other Lifestyle Disorders

2020 MENA Healthcare Life Sciences Predictions—KSA

2020 MENA Healthcare Predictions—UAE

2020 MENA Healthcare Predictions—Kuwait

2020 MENA Healthcare Predictions—Egypt

2020 MENA Healthcare Predictions—Algeria

2020 MENA Healthcare Predictions—Morocco

2020 Market Snapshot—Pharmaceuticals and Biotechnology

Key Growth Opportunities—Pharmaceuticals and Biotechnology

2020 Companies to Watch—Pharmaceuticals and Biotechnology

2020 Market Snapshot—IVD

Key Growth Opportunities—IVD

2020 Companies to Watch—IVD

Concluding Thoughts

Legal Disclaimer

Market Definitions—Pharmaceuticals and Biotechnology

Market Definitions—IVD

List of Exhibits

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
In this research deliverable, Frost & Sullivan’s analyst team provides bold perspectives and predictions for the Middle East and North Africa (MENA) region’s life sciences industry in 2020. The markets covered include pharmaceuticals, biotechnology, and in-vitro diagnostics. The analysis captures the impact of trends that are expected to transpire over 2019 and 2020 as organizations prepare for the future. This study provides guidance on where to find the greatest opportunities for expansion and which key companies to look out for. Frost & Sullivan projects the MENA Life Sciences market to cross US$ 40 billion by 2020. A shift in the focus of healthcare towards lifestyle-driven chronic health conditions and an increasingly affluent population’s preference for research-based branded drugs and preventive screening diagnostic tests are expected to drive the MENA life sciences market during the forecast period (2019 to 2020). Ongoing economic diversification and localization efforts by governments will make the domestic production of branded generic drugs more important than ever for both local consumption and export services. In addition, the regulatory environment will see a major transformation in each country. Given the on-going localization trends, it will be critical for global pharma MNCs to strategically collaborate with local agents or CMOs for their expertise on domestic contacts, customs regulations, and faster time to market in the MENA region. Areas exhibiting high growth opportunities will be the main focus of governments and industries alike. Business models specific to MENA will be pursued in contrast to those in larger markets of developed nations. Mergers and acquisitions are expected as stakeholders collaborate to achieve common outcomes. The outlook foresees increased collaboration and M&A activities between the life sciences and other healthcare sectors, in which preventative digital technology innovations will support the prevention of the onset of chronic and genetic diseases. Health spending is expected to rise in the region with governments aiming to meet sustainable development goals.--BEGIN PROMO--

Research Highlights

  • Market overview and projections for the MENA life sciences market in 2020
  • Revenue forecast by key MENA life sciences markets
  • Key predictions for the life sciences market in 2020 by segment
  • Key trends and growth opportunities affecting the MENA life sciences market
  • Strategic recommendations and future outlook of the life sciences market

Key Issues Addressed

  • What are the key predictions for the 2020 MENA life sciences market?
  • What is the market projection for MENA pharmaceutical/biotechnology and IVD markets for 2020?
  • Which are the most preferred countries in MENA for the localization of future drug manufacturing activities?
  • What are key growth opportunities in the MENA pharma and IVD industry for 2020?
  • Who are the companies to watch in the MENA region for the life sciences market?
  • What policies and regulatory developments will affect your company’s MENA operations in 2020?
  • What are the monetization opportunities for the life science industry as major GCC countries aim to diversify towards a service-based economy?

Author: Kamaljit Behera

More Information
No Index No
Podcast No
Author Takudzwa Musiyarira
Industries Healthcare
WIP Number PA76-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,99BF-B1,9611-B1,9627-B1